Nuclear factor-kappa B inhibition can enhance apoptosis of differentiated thyroid cancer cells induced by 131I

PLoS ONE

Volumn 7, Issue 3, 2012, Pages

  Meng, Zhaowei ^a   Lou, Shanshan ^a,b   Tan, Jian ^a   Xu, Ke ^a   Jia, Qiang ^a   Zheng, Wei ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b TIANJIN NORMAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4 METHYLPHENYLSULFONYL) 2 PROPENENITRILE; CASPASE 3; CELLULAR INHIBITOR OF APOPTOSIS PROTEIN 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INHIBITOR OF APOPTOSIS PROTEIN 1; IODINE 131; LIPOCORTIN 5; LUCIFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BCL XL; SMALL INTERFERING RNA; SYNAPTOTAGMIN I; TETRAZOLIUM; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS; 3-(4-METHYLPHENYLSULFONYL)-2-PROPENENITRILE; BCL2L1 PROTEIN, HUMAN; INHIBITOR OF APOPTOSIS PROTEIN; NITRILE; PROTEIN BCL X; RADIOACTIVE IODINE; RELA PROTEIN, HUMAN; SULFONE; TRANSCRIPTION FACTOR RELA; XIAP PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; CANCER CELL; CELL DIFFERENTIATION; CELL VIABILITY; CONTROLLED STUDY; DNA BINDING; DRUG EFFICACY; ENZYME INHIBITION; ENZYME REGULATION; ENZYME REPRESSION; FLOW CYTOMETRY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; PROTEIN FUNCTION; THYROID CANCER; WESTERN BLOTTING; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; METABOLISM; MULTIMODALITY CANCER THERAPY; NUCLEOTIDE SEQUENCE; RADIATION EXPOSURE; THYROID TUMOR; TUMOR CELL LINE;

APOPTOSIS; BASE SEQUENCE; BCL-X PROTEIN; CELL DIFFERENTIATION; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; IODINE RADIOISOTOPES; NF-KAPPA B; NITRILES; RNA, SMALL INTERFERING; SULFONES; THYROID NEOPLASMS; TRANSCRIPTION FACTOR RELA; TRANSFECTION; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 84858431097     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0033597     Document Type: Article

References (27)

1. Davies L, Welch HG, (2006) Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 295: 2164-2167.
2. Eustatia-Rutten CF, Corssmit EP, Biermasz NR, Pereira AM, Romijn JA, et al. (2006) Survival and death causes in differentiated thyroid carcinoma. J Clin Endocrinol Metab 91: 313-319.
3. Durante C, Haddy N, Baudin E, Leboulleux S, Hartl D, et al. (2006) Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab 91: 2892-2899.
4. Pfister DG, Fagin JA, (2008) Refractory thyroid cancer: a paradigm shift in treatment is not far off. J Clin Oncol 26: 4701-4704.
5. Tan J, Zhang G, Xu W, Meng Z, Dong F, et al. (2009) Thyrotoxicosis due to functioning metastatic follicular thyroid carcinoma after twelve I-131 therapies. Clin Nucl Med 34: 615-619.
6. O'Neill CJ, Oucharek J, Learoyd D, Sidhu SB, (2010) Standard and emerging therapies for metastatic differentiated thyroid cancer. Oncologist 15: 146-156.
7. Pacifico F, Leonardi A, (2010) Role of NF-kappaB in thyroid cancer. Mol Cell Endocrinol 321: 29-35.
8. Namba H, Saenko V, Yamashita S, (2007) Nuclear factor-kB in thyroid carcinogenesis and progression: a novel therapeutic target for advanced thyroid cancer. Arq Bras Endocrinol Metabol 51: 843-851.
9. Meng Z, Mitsutake N, Nakashima M, Starenki D, Matsuse M, et al. (2008) Dehydroxymethylepoxyquinomicin, a novel nuclear Factor-kappaB inhibitor, enhances antitumor activity of taxanes in anaplastic thyroid cancer cells. Endocrinology 149: 5357-5365.
10. Starenki D, Namba H, Saenko V, Ohtsuru A, Yamashita S, (2004) Inhibition of nuclear factor-kappaB cascade potentiates the effect of a combination treatment of anaplastic thyroid cancer cells. J Clin Endocrinol Metab 89: 410-418.
11. Starenki DV, Namba H, Saenko VA, Ohtsuru A, Maeda S, et al. (2004) Induction of thyroid cancer cell apoptosis by a novel nuclear factor kappaB inhibitor, dehydroxymethylepoxyquinomicin. Clin Cancer Res 10: 6821-6829.
12. Mitsiades CS, McMillin D, Kotoula V, Poulaki V, McMullan C, et al. (2006) Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro. J Clin Endocrinol Metab 91: 4013-4021.
13. Palona I, Namba H, Mitsutake N, Starenki D, Podtcheko A, et al. (2006) BRAFV600E promotes invasiveness of thyroid cancer cells through nuclear factor kappaB activation. Endocrinology 147: 5699-5707.
14. Karin M, (2006) Nuclear factor-kappaB in cancer development and progression. Nature 441: 431-436.
15. Duan J, Friedman J, Nottingham L, Chen Z, Ara G, et al. (2007) Nuclear factor-kappaB p65 small interfering RNA or proteasome inhibitor bortezomib sensitizes head and neck squamous cell carcinomas to classic histone deacetylase inhibitors and novel histone deacetylase inhibitor PXD101. Mol Cancer Ther 6: 37-50.
16. Wu X, Zhu Y, Yan H, Liu B, Li Y, et al. (2010) Isothiocyanates induce oxidative stress and suppress the metastasis potential of human non-small cell lung cancer cells. BMC Cancer 10: 269.
17. Weiss SJ, Philp NJ, Grollman EF, (1984) Iodide transport in a continuous line of cultured cells from rat thyroid. Endocrinology 114: 1090-1098.
18. Baud V, Karin M, (2009) Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov 8: 33-40.
19. Woyach JA, Shah MH, (2009) New therapeutic advances in the management of progressive thyroid cancer. Endocr Relat Cancer 16: 715-731.
20. Ganti AK, Cohen EE, (2006) Iodine-refractory thyroid carcinoma. Rev Recent Clin Trials 1: 133-141.
21. Pacifico F, Mauro C, Barone C, Crescenzi E, Mellone S, et al. (2004) Oncogenic and anti-apoptotic activity of NF-kappa B in human thyroid carcinomas. J Biol Chem 279: 54610-54619.
22. Visconti R, Cerutti J, Battista S, Fedele M, Trapasso F, et al. (1997) Expression of the neoplastic phenotype by human thyroid carcinoma cell lines requires NFkappaB p65 protein expression. Oncogene 15: 1987-1994.
23. Guo J, Verma UN, Gaynor RB, Frenkel EP, Becerra CR, (2004) Enhanced chemosensitivity to irinotecan by RNA interference-mediated down-regulation of the nuclear factor-kappaB p65 subunit. Clin Cancer Res 10: 3333-3341.
24. Wang C, Sheng G, Lu J, Xie L, Bai S, et al. (2012) Effect of RNAi-induced down regulation of nuclear factor kappa-B p65 on acute monocytic leukemia THP-1 cells in vitro and vivo. Mol Cell Biochem 359: 125-133.
25. Wu W, Yao D, Wang Y, Qiu L, Sai W, et al. (2010) Suppression of human hepatoma (HepG2) cell growth by nuclear factor-kappaB/p65 specific siRNA. Tumour Biol 31: 605-611.
26. Kucharczak J, Simmons MJ, Fan Y, Gelinas C, (2003) To be, or not to be: NF-kappaB is the answer-role of Rel/NF-kappaB in the regulation of apoptosis. Oncogene 22: 8961-8982.
27. Marx K, Moka D, Schomacker K, Fischer T, Gabruk-Szostak B, et al. (2006) Cell death induced by 131 I in a differentiated thyroid carcinoma cell line in vitro: necrosis or apoptosis? Nucl Med Commun 27: 353-358.